This is associate exciting time within the treatment of acute lymphocytic leukemia (ALL) given the advances within the relapsed/refractory setting. the event of protein treatments (including protein drug conjugates with toxins) offers a special treatment approach compared with standard therapy regimens. Moreover, the utilization of bispecific T-cell-engager antibodies (BiTEs) like blinatumomab harness the cytotoxic activity of T cells against CD19-positive lymphoblasts. Another strategy involves the utilization of mythical creature matter receptor (CAR) T cells. automotive T cells have incontestable promising leads to the relapsed/refractory setting.